ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Rabeprazole

Also written as “rabeprazole”, “rabeprazole sodium” and “E3810”.

Its studies are mostly in Gastroesophageal Reflux · Esophagitis, Peptic · Gastrointestinal Diseases · Stomach Ulcer · Heartburn, led by 13 companies.

Drug pageRabeprazole: every studyMany companies study it; this page follows only the 56 they lead. All 105 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 12, 200556 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisaiits history only210 open or runningphase 3since Sep 12, 2005Aug 19, 2005none ahead
Johnson & Johnsonits history only150 open or runningphase 4since Sep 13, 2005Sep 13, 2005none ahead
Pfizerits history only40 open or runningphase 1since Mar 24, 2014Mar 24, 2014none ahead
GlaxoSmithKlineits history only30 open or runningphase 4since May 14, 2015Sep 26, 2013none ahead
Viatrisits history only30 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Lomond Therapeuticsits history only20 open or runningphase 1since May 1, 2024May 1, 2024none ahead
Torrent Pharmaceuticalsits history only20 open or runningphase 1since Nov 15, 2013Nov 15, 2013none ahead
Boehringer Ingelheimits history only10 open or runningphase 1since May 16, 2022May 16, 2022none ahead
Chong Kun Dang Pharmaceuticalits history only10 open or runningphase 4since May 20, 2013May 20, 2013none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Jun 15, 2015Jun 15, 2015none ahead

Also a collaborator on its studies: Ono Pharmaceutical and Pierre Fabre Laboratories.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Genuine Research Center, Egypt only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 15, 2015First study: phase 1 study in HealthyFirst studyNCT02477306 · 60 enrolled · Egypt

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

The one study Genuine Research Center, Egypt leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02477306Healthy · Egypt1CompletedMar 201460

How it is read

Names in the registry

  • “Rabeprazole”, 15 entries
  • “rabeprazole”, 14 entries
  • “rabeprazole sodium”, 10 entries
  • “E3810”, 8 entries
  • “Rabeprazole sodium”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.